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Abstract
Background—African Americans suffer from higher prevalence and severity of atherosclerosis
compared to Whites, highlighting racial and ethnic disparities in cardiovascular disease. Previous
studies have pointed to the role of vascular inflammation and platelet activation in the formation
of atherosclerotic lesions.
Methods and Results—We explored the role of genetic variation in four chemokine/
chemokine receptor genes (CX3CR1, CX3CL1, CXCR3 and PF4) on systemic inflammation and
platelet activation serum biomarkers (fractalkine, platelet P-selectin, PF4 and TNFα). In total, 110
SNPs were tested among 1,042 African Americans and 763 Whites. The strongest association with
serum PF4 levels was observed for rs168449, which was significant in both racial groups (P-
value: African Americans=0.0017, Whites=0.014, Combined=1.2×10−4), and remained significant
after permutation-based multiple corrections (Pc-value: Combined=0.0013). After accounting for
the effect of rs168449, we identified another significant SNP (rs1435520) suggesting a second
independent signal regulating serum PF4 levels (conditional P-value: African Americans=0.02,
Whites=0.02). Together these SNPs explained 0.98% and 1.23% of serum PF4 variance in African
Americans and Whites, respectively. Additionally, in African Americans, we found an additional
PF4 variant (rs8180167), uncorrelated with rs168449 and rs1435520, associated with serum
TNFα levels (P-value=0.008, Pc-value=0.048).
Conclusions—Our study highlight the importance of PF4 variants in the regulation of platelet
activation (PF4) and systemic inflammation (TNFα) serum biomarkers.
Corresponding Authors: Dan E. Arking, PhD, McKusick-Nathans Inst of Genetic Med, Johns Hopkins University, 733 N. Broadway,
Room 453, Baltimore, MD 21205, Tel: (410) 502-4867, Fax: (410) 614-8600, arking@jhmi.edu. Craig Fletcher, DVM, PhD, Dept of
Pathology & Laboratory Med, University of North Carolina at Chapel Hill, 1106 Bioinformatics Building CB#7115, Chapel Hill, NC
27599-7115, Tel: (919) 843-9605, Fax: (919) 843-9340, craig_fletcher@med.unc.edu.
Conflict of Interest Disclosures: None.
NIH Public Access
Author Manuscript
Circ Cardiovasc Genet. Author manuscript; available in PMC 2013 December 16.
Published in final edited form as:














association study; atherosclerosis; inflammation; platelets; Chemokines; PF4; TNF-alpha
Introduction
Over the past decade, epidemiological studies comparing African Americans and other
minority groups to Whites have demonstrated persistent disparities in morbidity and
mortality.1, 2 In particular, a disproportionately high prevalence and severity of
atherosclerotic cardiovascular disease in African Americans is observed. The reasons for
this health disparity are multiple and largely unresolved.3 Atherosclerosis is a lifelong
progressive disease, which leads to myocardial infarction (MI), stroke, and higher mortality
rates.4 This disease was formerly characterized by the accumulation of lipids and fibrous
elements in large arteries; but in recent years, substantial advances in basic and experimental
science have illuminated the importance of vascular inflammation5, 6 and platelet activation
in disease etiology.7 However, the underlying cellular and molecular mechanisms that
contribute to atherogenesis are not fully known. It has been suggested that continuous
immigration and infiltration of activated macrophages and T cells into and within
atherosclerotic lesions are critical events during the initial phase of plaque formation, 8
progression, and even in acute complications such as plaque rupture and thrombosis.9 The
recruitment of these cells to lesions is largely guided by chemokines, and contributes to the
accumulation of inflammatory cells in the atherosclerotic plaque.10
Chemokines constitute a family of structurally related chemotactic cytokines and classified
into subgroups (CC, CXC, C, CX3C) based on the position of the conserved cysteine
residues in the amino-terminal region of the molecule. In addition to the regulation of
trafficking of macrophages and T cells, chemokines are also involved in platelet
activation.11, 12 Fractalkine (CX3CL1) is not produced by endothelial cells under
physiologic conditions in vivo, however its production is induced via inflammatory signals
(i.e. TNFα), vascular injury, or atherosclerosis. Monocytes and platelets are known to
interact directly with membrane-bound CX3CL1, and fractalkine receptor (CX3CR1) and
CXCR3 are well documented in the recruitment of inflammatory cells. Previous studies have
demonstrated the presence of a functional CX3CR1 on human platelets.5 Blood platelets are
mainly involved in hemostasis and acute thrombus formation, but also have pro-
inflammatory and growth-regulatory properties that contribute to the progression of
atherosclerosis.13, 14 The activation of platelets leads to the release of a wide range of
growth factors, inflammatory mediators (including chemokines, e.g., platelet factor 4), and
adhesion molecules (e.g., P-selectin). Previous studies have suggested that platelet activation
also induces the expression of pro-inflammatory TNFα and chemokines in monocytes/
macrophages.15 Compelling evidence from functional16–18 and genetic studies19, 20 also
affirms a link between chemokines and the progression of atherosclerosis. Prior studies have
shown that activated platelets can stimulate endothelial cells, leading to an increase in
leukocyte rolling along the vessel wall.21 However, the mechanisms by which platelets
activate endothelial cells and vascular inflammation is not well understood. Platelet factor 4
(PF4, or CXCL4) is a chemokine stored in platelet alpha-granules and released during
platelet activation.10, 22–24. Our prior work demonstrated PF4 role in T cell trafficking and
development of experimental cerebral malaria.25
Given the importance of systemic inflammation and platelet activation to the development
of atherosclerosis, we explored the role of genetic variants in regulating these processes.
Indeed, these two processes yield predictive and prognostic information of considerable
clinical utility. Based on our current understanding, we assume a model in which
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inflammatory mediators can lead to platelet activation, which in turn intensify the
inflammatory response, thus forming an atherogenic amplification loop. The key
inflammatory mediators on which we focused are chemokines and chemokine receptors;
fractalkine receptor (CX3CR1), fractalkine (CX3CL1), chemokine (C-X-C motif) receptor 3
(CXCR3) which serves as a receptor for PF4, and platelet factor (PF4). The systemic
inflammation and platelet activation serum biomarkers; fractalkine, platelet-selectin (P-
selectin), platelet factor 4 (PF4) and tumor necrosis factor-alpha (TNFα) were assessed as
vascular risk factors for atherosclerosis. The overall goal of this study is to explore the
influence of genetic variations in CX3CR1 and CXCR3 and determine if they are
asymmetrically distributed in African Americans compared to Whites, or if they modulate in
the chemokine/chemokine receptors on the systemic inflammation and platelet activation
serum biomarkers in African Americans and Whites.
Materials and Methods
Study Cohort
Study samples were drawn from participants of Healthy Aging in Neighborhoods of
Diversity across the Life Span (HANDLS) study of the National Institute on Aging
Intramural Research Program.26 HANDLS is a prospective longitudinal study of
approximately 4,000 African American and White adults from Baltimore City, Maryland.
The purpose of the HANDLS study is to unravel the effects of race and socioeconomic
status (SES) on the development of age-associated health disparities over a 20-year period.
Subjects were enrolled from 2004 to 2008 by household screenings from an area probability
sample of 13 neighborhoods defined by contiguous US Census tracts in the city of
Baltimore. These tracts were selected because they were likely to yield representative
distributions of individuals who were 30 – 64 yrs old, African Americans or Whites, males
and females, and had a household income either < 125% or >= 125% of the federal poverty
level. Multi-ethnic individuals were included provided they identified themselves as African
Americans or Whites, but not both. To be included in the HANDLS study, participants must
(1) be within age range of 30 – 64 yrs at baseline, (2) be able to give informed consent, (3)
be able to perform at least 5 measures of the following evaluations: laboratory evaluation,
medical history, physical examination, physical performance, cognitive testing, dietary
recall, audio questionnaire, body composition, carotid Doppler, or pulse wave velocity
assessment, (4) have valid picture identification, and (5) have a verifiable address at the time
of entry. Exclusions included participants who were pregnant at the time of entry, had a
diagnosis of AIDS, and were within 6 months of active treatment of cancer (chemotherapy,
biologic, or radiation). Details of the study design are given elsewhere.26 Briefly, the data
used herein consists of 1,920 community-dwelling African American and White Baltimore
City residents, who were enrolled after providing written informed consent and had
available serum biomarker data. The MedStar Institutional Review Board approved this
protocol.
Assessment of serum biomarkers
Measurements of the serum biomarkers were evaluated on cryopreserved (−80 C°) serum
aliquots. The serum samples were divided into four aliquots and each aliquot was used for
the assessment of one of the four biomarkers (fractalkine, P-selectin, PF4 and TNFα). Both
serum biomarker data and DNA genotypes were available for 1,920 HANDLS participants
(Whites, n=828; African Americans, n=1092). Commercial MSD kits (Meso Scale
Discovery, Gaithersburg, Maryland 20877) were used for the measurement of serum
fractalkine (Customized Fractalkine single-Plex assay kit, Cat # N45ZA-1), PF4
(Customized PF4 Single-Plex assay kit, Cat # N45ZA-1), P-selectin (Cataloged P-Selectin
Single-Plex assay kit, Cat # N451ENB-1) and TNFα (Cataloged Human ProInflammatory 9-
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Plex Assay Ultra-Sensitive Kit, Cat # K15007C-4) levels. Dilution factors were determined
using naive serum samples before the sample testing and measurements were made
according to manufacturer’s instructions. All the serum assessments were performed in
duplicate.
SNP Selection, Genotyping and Quality Control
For each gene, we selected SNPs using two criteria. First, all the known missense and
previously associated SNPs were selected for genotyping, and then additional tag SNPs27
were selected from HapMap phase I, II & III, using YRI and CEU datasets. All the tag SNPs
were captured from the 20 kb flanking 5′ and 3′ regions of the CX3CL1, CX3CR1, CXCR3
and PF4 genes with minor allele frequency (MAF) >1% and r2 ≥0.8. Given the proximity of
nearby genes to our genes of interest, some of the flanking SNPs lie in nearby genes. A total
of 137 tag SNPs from the 4 genes (CX3CL1, n=30; CX3CR1, n=68; CXCR3, n=9; and PF4,
n=30) were selected and grouped in 4 separate pools for genotyping using iPLEX Gold
single base-pair extension with MALDI-TOF mass spectrometry (Sequenom MassArray).
Quality control (QC) for both samples and SNPs was performed separately for each
Sequenom genotyping pool, and the following inclusion/exclusion criteria were applied:
SNPs with >5% missingness (23 SNPs) and monomorphic SNPs (4 SNPs) were excluded,
and after removal of these SNPs, samples with >50% missingness (reflecting poor quality
DNA and/or poor genotyping) were removed. A sensitivity analysis using a stringent sample
missingness exclusion threshold of >5% demonstrated no meaningful difference in results
(data not shown). After QC, 110/137 SNPs were analyzed in 1,805 (94%) individuals
(Whites, n=763; African Americans, n=1042). The allele frequency comparison of the
directly genotyped 110 SNPs with the HapMap (phase I, II & III) CEU and ASW
population, confirmed the quality of the genotyped data and all the SNPs are in Hardy-
Weinberg equilibrium.
Statistics
Before assessing genetic associations, serum biomarker levels in the studied samples were
evaluated for normality and appropriate transformation was applied on each biomarker
(fractalkine - log transformed, P-selectin - square root transformed, PF4 - log transformed,
TNFα-inverse log transformed). Association analysis and quality control measures were
performed using PLINK software package28 version 1.06 (http://pngu.mgh.harvard.edu/
purcell/plink/). To assess the influence of genetic variation in the chemokine/chemokine
receptors on the systemic inflammation and platelet activation serum biomarkers, all
analyses were stratified by race and adjusted for age and sex in a multivariate linear
regression, assuming an additive genetic model of inheritance. To create a more
comprehensive fine map of the locus, imputation was performed using Hidden Markov
model as implemented in the MaCH software29(version 1.0.16) (http://www.sph.umich.edu/
csg/abecasis/MACH/). The CEU and CEU-YRI combined panel, from the 1000 Genomes
Project,30 were used as reference populations for Whites and African American,
respectively. Imputation was performed in two steps and QC was performed both before and
after imputation. In step 1, model parameters were estimated using 100 iterations and,
thereafter, allele dosage and maximum likelihood genotypes were imputed in step 2. To
account for the uncertainty of the imputed data, the estimated allele dosage for each SNP
was analyzed using ProABEL31 under a linear regression framework. Standard quality
metrics were applied and only SNPs with high quality score (RSq > 0.8) were analyzed.
Linkage disequilibrium (LD) patterns within the surrounding region of the significant SNPs
were constructed using the solid spine method, as implemented in Haploview32 (version 4.1)
(http://www.broad.mit.edu/mpg/haploview/index.php). For each defined gene region,
permutation-based multiple test correction was performed using 5000 permutations. To
determine independent genetic effects, multivariate conditional regression analyses were
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performed using allele dosage data. To identify known functional regulatory variants within
or in proximity to the region of interest, the GTEx (Genotype-Tissue Expression) expression
quantitative trait loci (eQTL) database was queried (http://www.ncbi.nlm.nih.gov/gtex/test/
GTEX2/gtex.cgi).33 Further, a long-range haplotype test was utilized to detect recent
selection and the inferences were made using integrated haplotype score (iHS), as described
elsewhere.34
Results
Detailed demographic and clinical characteristics of the studied 1,805 samples are shown in
Table 1 and Supplementary Table 1. The average age of the studied cohort was 48 yrs, with
~45% males.
Association of PF4 genetic variation with serum PF4 levels
Initially, 24 SNPs chosen to tag the PF4 gene (see Methods) were tested for association with
PF4 serum levels using linear regression models, adjusting for age and sex. In African
Americans 3 SNPs were nominally associated with PF4 levels (P-value <0.05), and in
Whites, 8 SNPs were nominally associated, with 3 SNPs in common, all showing the same
direction of effect in both populations, suggesting the presence of a shared genetic
association in African Americans and Whites (Table 2). In a joint analysis, adjusting for age,
sex, and race, 6 of the SNPs were associated with PF4 levels, with the most significant effect
observed for rs183028 (P-value: 2.7×10−4) (Table 2). The ancestral allele (A) of rs183028 is
the minor allele and is significantly associated with higher serum PF4 levels in both racial
groups (African American: β=0.06, SE=0.02; Whites: β=0.09, SE=0.04). The frequency of
this allele (A) in Whites was 9%, compared to 41% in African Americans. Given the large
allele frequency difference, we explored the possibility of population-specific selection
pressure at this locus. To detect signal for recent positive selection, we used iHS statistics,34
based on differential levels of linkage disequilibrium (LD) surrounding a positively selected
allele compared to the background allele at the same position, and no evidence of selection
was observed (data not shown).
To fine map the observed genetic effect and potentially identify additional independent
effects, we imputed ungenotyped SNPs over a 30-kb interval centered on rs183028 using the
1000 Genomes reference panels.30 In total, 66 SNPs were imputed, and after removing
poorly imputed SNPs (RSq < 0.8), 44 SNPs were analyzed. The strongest evidence for
association was observed in a region of high LD, encompassing the PF4, PPBP (pro-platelet
basic protein) and CXCL5 (C-X-C motif ligand 5) genes (Figure 1a, 1b). In this region, 30
SNPs showed nominal association (P-value < 0.05) with PF4 serum levels (Table 3). In
African Americans, the most significant association was observed for rs168449 (P-value =
0.0017), where the T allele (frequency 41%) was associated with higher PF4 serum levels
(β= 0.05, SE=0.02). This SNP is ~1.3 kb upstream of rs183028, with which it is highly
correlated in both racial groups (African Americans: r2=0.97; Whites: r2=1.0) (Figure 1a,
1b). The association of rs168449 with serum PF4 levels remained significant (Pc-value =
0.02) even after gene-wide permutation-based multiple correction (Table 3). Similarly, in
Whites, this SNP showed nominal significance (P-value = 0.014) with the same direction
effect (T allele, β= 0.09, SE=0.04) (Table 3). The serum PF4 variance explained by
rs168449 is 0.58% and 0.64% in African Americans and Whites, respectively. In a joint
analysis of both racial groups, rs168449 was the most significant SNP (P-value = 1.2×10−4,
Pc-value = 0.0013) from this region, (Table 3), and the distributions of the serum PF4 levels
within each genotype group of rs168449 are shown in Figure 2. Individuals who were
homozygous for the T allele have higher serum levels compared to those homozygous for
the major allele (C) (Figure 2). Given the small number of individuals in the T allele
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homozygous group, we also tested the association under a dominant genetic model. In both
racial groups rs168449 maintains significance assuming a dominant model of inheritance (P-
value: African Americans=0.02, Whites= 0.009, Combined=0.001). To test for genetic
effects independent of rs168449, we performed conditional multivariate regression analysis.
After accounting for the effect of rs168449, rs1429637 and rs1435520 still showed
significant association (Table 3). Notably, these SNPs are not in LD with rs168449 (r2=0) in
both racial groups, but are in strong LD with each other (r2=0.88 and 0.51 in Whites and
African Americans, respectively); thus likely representing the same genetic signal (Figure
1a, 1b). These two SNPs are directly genotyped and rs1435520 showed greater significance
in both African Americans (conditional P-value: 0.022) and Whites (conditional P-value:
0.02). Given the small number of homozygous rare allele individuals observed for
rs1435520, we also tested genetic association of serum PF4 levels under a dominant genetic
model, combining the rare homozygotes and heterozygous individuals (Supplementary
Table 2). As seen with the additive model, both SNPs, rs1429637 (P-value: African
Americans=0.06; Whites=0.011 and Combined=0.0016) and rs1435520 (P-value: African
Americans=0.045; Whites=0.0084 and Combined=0.0009), maintain a significant
association. In both racial groups, rs1435520 explains more PF4 variability than rs1429637,
explaining 0.46% and 0.77% of the variance in African Americans and Whites, respectively.
Since, rs168449 is an imputed SNP, we also performed conditional multivariate analysis
with a directly genotyped SNP which is in complete or high correlation with rs168449,
rs183028 (African Americans: r2=0.97; Whites: r2=1.0). As expected, we only observed
significant associations with rs1429637 and rs1435520, confirming the presence of two
independent loci (rs168449 and rs1435520) regulating serum PF4 levels (Supplementary
Table 3). Combined, these two loci explain 0.98% (African Americans) and 1.23% (Whites)
of the variability in serum PF4 levels.
Association of PF4 genetic variation and serum TNFα levels
We also assessed the effect of PF4 variants on three additional serum biomarkers
(fractalkine, P-selectin and TNFα), and we observed significant association with TNFα
serum levels. The most significant association was seen in African American for rs8180167
(β= 0.016, SE=0.006, P-value = 0.008), however, this SNP did not show an effect in Whites
(β= 0.003, P-value = 0.66) (Supplementary Table 4). rs8180167 is ~12.0 kb and ~17.2 kb
upstream of rs1435520 and rs168449, respectively, and is largely uncorrelated within
African Americans (rs1435520 r2=0 and rs168449 r2=0.04) (Supplementary Figure 1). The
association of rs8180167 remained significant after multiple test correction (Pc-value =
0.048), and no other SNPs in the region show association after accounting for the effect of
rs8180167 (Supplementary Table 4). rs8180167 explains ~1.3% of serum TNFα variance.
CX3CL1, CX3CR1 and CXCR3 genetic variations and serum biomarker levels
In total, 86 SNPs tagging the remaining 3 genes were tested for all 4 serum biomarkers. We
did not detect any influence of these SNPs on biomarker levels in either of the racial groups,
or in the combined analysis after gene-wide permutation corrections. In addition, the
CX3CR1 gene, which encodes a chemokine receptor for fractalkine, contains two non-
synonymous SNPs, rs3732378 (Thr280Met) and rs3732379 (Val249Ile), that were
previously associated with reduced prevalence of atherosclerosis and acute coronary
events.35,36 In Whites, we observed a nominally significant association of serum fractalkine
levels with Thr280Met (P-value = 0.05) (Supplementary Table 5). Given a priori evidence
of this variant, we reported the uncorrected P-value and results should therefore be
interpreted with caution. Surprisingly, the observed effect estimates for rs3732378
(Thr280Met) is in the opposite direction as those previously reported for serum fractalkine.
As opposed to the known athero-protective effect of 280Met, the allele A (Met) was
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observed associated with higher serum fractalkine levels (β=0.05, SE=0.02) (Supplementary
Table 5). Neither SNP showed any significance with the other serum biomarkers.
Discussion
Atherosclerosis is a systemic disease that is responsible for most cardiovascular events and
stroke. 4 Given the importance of the inflammatory and platelet activation cascade in the
pathogenesis of disease, 5–7 clinical interest has focused on the identification of biomarkers
for atherosclerotic risk prediction. Epidemiological studies have demonstrated that African
Americans have higher prevalence and disease severity compared to Whites.1, 2 The reason
for this differential atherogenic susceptibility are multiple and largely unresolved. In this
study, we investigated the influence of genetic variation in the chemokine/chemokine
receptors on systemic inflammation and platelet activation serum biomarkers.
We performed a comprehensive genetic screen of 4 genes (CX3CL1, CX3CR1, CXCR3 and
PF4), and report PF4 locus variants associated with the modulation of serum PF4 and TNFα
levels. For serum PF4 levels, the most significant association was observed for rs168449,
which showed consistent effect in both African American and White populations. In African
Americans, allele T (frequency 41%) was associated with higher levels (Table 3), whereas,
in Whites, this allele showed the same direction effect but had a ~4.5-fold lower frequency
(T allele frequency 9%). In the combined dataset, rs168449 maintained a robust association,
and suggested the potential involvement in the modulation of serum PF4 levels in both racial
groups. While accounting for the effect of rs168449, we also report another SNP
(rs1435520) as a second independent signal regulating serum PF4 levels from this region.
Together these SNPs explained 0.98% and 1.23% of serum PF4 variance in African
Americans and Whites, respectively. Our study also identified the association of another
independent SNP (rs8180167) regulating pro-inflammatory serum TNFα levels. In race
stratified analysis, this association was observed only in African Americans, and revealed
significant differences in allele frequencies between the two cohorts (Supplementary Table
4). While the frequencies of the ancestral allele (A) in African American and Whites were
substantially different, 75% and 18%, respectively, we did not observe any evidence for
recent selection at this locus. In an attempt to identify potentially functional variants in this
locus, we looked for known expression quantitative trait loci (eQTLs) using the Genotype-
Tissue Expression (GTEx) database, which queries lymphoblastoid, liver, brain cerebellum,
frontal cortex, temporal cortex tissues, but found no known eQTLs in this region.
As shown in Figure 1a and 1b, these three PF4 region SNPs (rs168449, rs1435520 and
rs8180167) are intergenic SNPs and lie close to the PPBP and CXCL5 genes, which are
known to encode inflammatory cytokines. The PPBP gene encodes platelet-derived growth
factor and function as a potent chemo-attractant and activator of neutrophils. Neutrophils are
the most prominent leukocytes in acute inflammatory reactions and contribute in a number
of inflammatory conditions. Recently, Rotzius et al examined the role of neutrophils in a
mouse model of atherosclerosis and noticed that neutrophils accumulate in atherosclerotic
lesions.35 Moreover, neutrophils are the predominant immune cells in the high inflammatory
shoulder regions of plaques, suggesting that these cells may play an important role in the
immunological processes of atherogenesis. Similarly, CXCL5 (C-X-C motif ligand 5) is also
implicated in the chemotaxis of inflammatory cells and previously shown to be a recruiter of
neutrophils and involved in their activation. In accordance to these reports, our results
suggest the plausible involvement of PF4, PPBP, and/or CXCL5 genes in the modulation of
serum PF4 and pro-inflammatory TNFα levels.
Our study also confirms the role of a CX3CR1 missense variant (Thr280Met) that has
previously been reported associated with reduced prevalence of atherosclerosis and acute
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coronary events.36,37 Previously, the CX3CR1-280Met mutant was demonstrated to have an
athero-protective effect 38 and showed a marked reduction in the kinetics of fractalkine
binding. 38 The mutant form of CX3CR1 was also associated with reduced fractalkine-
induced chemotactic activity 39 and dysfunction of the receptor.39–42 In this study, we
observed a significant association of serum fractalkine levels with Thr280Met, but
surprisingly the observed effect of 280Met allele is in the opposite direction as those
reported previously. In Whites, we observed higher fractalkine levels associated with this
allele, whereas no significant association was observed in African Americans.
Previously, it has been shown that PF4 is localized to fatty streaks and atherosclerotic
lesions. 43 To assess the role of PF4 in the formation of atherosclerotic lesions, Sachais et al
investigated the effects of knocking out PF4 expression in mice and showed a significant
decrease in lesion formation in the absence of PF4. 44 This finding provides in vivo evidence
that establishes that elimination of PF4 is athero-protective. Given the current knowledge
available for the role of PF4 in atherosclerosis, our study demonstrates the importance of
PF4 gene variants in the modulation of serum PF4 and pro-inflammatory TNFα levels. In
our study, we assumed a model in which inflammatory responses lead to platelet activation,
which can in turn intensify the inflammatory responses. This model contains regulatory
elements that are known risk factors for atherosclerotic cardiovascular disease but has
several important limitations that merit discussion. First, given the importance of the platelet
activation and inflammatory mediators in the progression of atherosclerosis, we only tested
4 genes in our study and possibly other genes have a greater biological impact on these
alterations. Through this study, we observed that PF4 SNPs explain a small proportion
(~1%) of genetic variability for serum PF4 and TNFα levels; hence, suggesting the
involvement of other genes contributing alterations in serum levels. Second, our study is
only limited to the association of the systemic inflammation and platelet activation serum
biomarkers, whereas exploring sub-clinical measures of atherosclerosis (carotid intima
media thickness, pulse wave velocity, heart rate variability etc.) might have high biological
relevance in context to atherosclerosis. Furthermore, while we have performed multiple test
correction for each gene, we have not additionally corrected for the four traits studied.
Knowing that the genetic puzzle of atherosclerotic cardiovascular disease will be complex
and involve genes/loci from multiple biologic pathways, the next step will be to understand
the relationships between disease risk loci important in innate and adaptive immunity,
inflammation, blood pressure control and vascular reactivity and other factors. However,
most critical will be an approach that keeps in mind that the relative risks of disease have
different weights in the process of disease development and considerable influence
especially when taken in the context of gene-environment interactions.45–48 Examining
those demonstrated to affect the risk of disease in African Americans might allow us to work
towards a model that includes blood pressure control loci SLC24A4 (rs11160059;
rs17783630) and incident coronary heart disease loci PFTK1 variant (rs1859023) identified
to be important in African Americans.49,50 Our finding in PF4 highlights the possible
relevance of markers of systemic inflammation in atherosclerotic heart disease among
African Americans. These findings should be put in a model with other loci important in
modulating levels of acute phase reactants like C-reactive protein and other inflammatory
molecules. The disparity in the incidence and severity of atherosclerotic cardiovascular
disease is linked to unique inter-relationships between differentially expressed gene loci
from different molecular pathways and ultimately with their interaction with the
environment.
In conclusion, our results overall indicate that PF4 genetic variants are likely involved in the
alterations of serum PF4 levels in both African American and White populations. We also
demonstrate that another PF4 variant (rs8180167) has a race specific effect in the regulation
of serum TNFα levels in African Americans. Taken together, these results highlight the
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importance of PF4 genetic variation in the regulation of systemic inflammation (TNFα) and
platelet activation (PF4) serum biomarkers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Given the importance of systemic inflammation and platelet activation to the
development of atherosclerosis, we explored the role of genetic variants in regulating
these processes. We performed a comprehensive genetic screen of 4 genes (CX3CL1,
CX3CR1, CXCR3 and PF4), and report PF4 locus variants associated with the
modulation of serum PF4 and TNFα levels. For serum PF4 levels, the most significant
association was observed for rs168449, which showed consistent effect in both African
American and White populations. In African Americans, allele T was associated with
higher serum levels of PF4, whereas, in Whites, this allele showed the same direction
effect but had a several fold lower frequency. Our study also identified the association of
another independent SNP (rs8180167) regulating pro-inflammatory serum TNFα levels.
In conclusion, our results overall indicate that PF4 genetic variants are likely involved in
the alterations of serum PF4 levels in both African American and White populations. We
also demonstrate that another PF4 variant (rs8180167) has a race specific effect in the
regulation of serum TNFα levels in African Americans. Taken together, these results
highlight the importance of PF4 genetic variation in the regulation of systemic
inflammation (TNFα) and platelet activation (PF4) serum biomarkers. Knowing that the
genetic puzzle of atherosclerotic cardiovascular disease will be complex and involve
genes/loci from multiple biologic pathways, the next step will be to understand the
relationships between disease risk loci important in innate and adaptive immunity,
inflammation, blood pressure control and vascular reactivity and other factors.
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Schematic representation and LD pattern of the 4q12-q31 region SNPs. The upper panel
shows the location of the PF4, PPBP and CXCL5 genes and neighboring significant SNPs
(n=30). In the middle panel, imputation quality of these SNPs is shown as RSq (squared
correlation between imputed and true genotypes) and directly genotyped SNPs are marked
as 1. (1a) The bottom panel shows LD pattern of these SNPs in African Americans,
constructed using Haploview (version 4.1) software (http://www.broad.mit.edu/mpg/
haploview/index.php). Numbers within diamonds and degree of shading represents the
magnitude of the pair-wise LD (measured as r2, black to white gradient reflecting higher to
lower LD values). The observed most significant SNP with serum PF4 levels is highlighted
in bold. For Whites, the pair-wise correlation of these SNPs is shown in Figure 1b.
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Distribution of serum PF4 levels. The histogram displays the mean values of transformed
serum PF4 levels stratified by genotype at the rs168449 locus. The 95% confidence interval
(CI) around the mean is represented as vertical bars and number above the bars indicate
individual counts observed for the respective genotype group.
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Table 1
Demographic and clinical characteristics
Characteristics African Americans Whites P-value*
Samples, n (%) 1042 (57.7) 763 (42.3)
Sex, n (%)
 Males 472 (45.3) 341 (44.7) 0.79
Age (in years), mean ± SD 48.18 ± 8.9 48.39 ± 9.3 0.51
Poverty Status¶, n (%)
 Below 125% 518 (49.7) 261 (34.2) <0.001
Serum Biomarkers, mean ± SD
 Fractalkine (pg/mL) 895.7 ± 438.8 835.9 ± 334.7 < 0.001
 P-selectin (ng/mL) 104.1 ± 34.4 108.7 ± 37.1 0.018
 Platelet factor 4 (ng/mL) 18098 ± 10796 20285 ± 19480 < 0.001
 TNFα† (pg/mL) 14.1 ± 22.4 13.98 ± 23.1 0.002
Diabetes, n (%) 138 (13.2) 98 (12.8) 0.58
Hypertension, n (%) 406 (38.9) 227 (29.7) <0.001
Cigarette smoking, n (%) 0.54
 Never smoked 195 (18.7) 165 (21.6)
 Smoked, never regularly 91 (8.7) 65 (8.5)
 Former smoker 186 (17.8) 143 (18.7)
 Current smoker 452 (43.4) 319 (41.8)
 Not known 118 (11.3) 71 (9.3)
Total Cholesterol 185.6 ± 44.4 191.2 ± 42.5 0.005
LDL‡ (mg/dL) 108.1 ± 38.6 112.9 ± 36.7 0.004
HDL§ (mg/dL) 55.94 ± 18.6 48.35 ± 14.1 <0.001
*
P-values for continuous and categorical variable comparisons were generated using wilcoxon rank sum and pearson chi-square test, respectively.
¶
Poverty status was determined whether a participant reported an annual household income <125% or >125% of the 2004 Department of Health
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